• Nutritional-GICompleted with Results

  ASSURE: Study of Relizorb in people with CF who receive enteral tube feeding , protocol number Alcresta 0000498

  This study evaluated the safety, tolerability and effectiveness of RELiZORB® cartridge. RELiZORB® cartridge is a digestive enzyme cartridge for people using enteral nutrition (EN) tube feedings that breaks down fats in enteral nutrition tube feeding formula.

  • Age:

    4 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    Less than 100%

  • Number of Visits:

    5

  • Length of Participation:

    4 months

• Nutritional-GICompleted with Results

  Study of in-line digestive enzyme cartridge (Relizorb) in people with CF who are currently receiving enteral tube feedings , protocol number Alcresta 0000497

  This study looked at the safety and effectiveness of Relizorb®, a new digestive enzyme cartridge designed for people with pancreatic insufficiency (PI) that can be used in-line with enteral tube feeding. This cartridge delivers the digestive enzyme lipase, which helps the body digest fats contained in the tube-feeding formula.

  • Age:

    4 Years to 82 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    Less than 100%

  • Number of Visits:

    4

  • Length of Participation:

    27 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.